Drugs / Ulonivirine
Ulonivirine
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05093972 | Jan → Jun 2027 expected | liver disorder | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07595263 | Aug 2026 → Jan 2027 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07530289 | Apr → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07305831 | Jan → Apr 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07334886 | Sep → Nov 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06619678 | Jan → Jun 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02174159 | Sep 2014 → Jul 2015 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06891066 | Apr 2025 → Aug 2027 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04564547 | Mar 2021 → Jan 2025 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07266831 | Dec 2025 → Mar 2029 expected | HIV infectious disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulonivirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02174159 ↗ |
| Known as | [14C]Ulonivirine | “A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)” NCT07334886 ↗ |
| Known as | MK-8507 | “A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)” NCT07530289 ↗ |
| Known as | ULO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891066 ↗ |
| Known as | Ulonivirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095253 ↗ |
| Modality | Small molecule | — CHEMBL5095253 ↗ |
| Route | Oral | “Ulonivirine tablet taken by mouth.” NCT04564547 ↗ |